Sign up for the QMED & MD+DI Daily newsletter.
Boston Scientific's Corporate Warning Letter Sticking Until Mid-'07
The corporate warning letter FDA issued to Boston Scientific is not likely to be lifted before mid-2007, company executives said in a conference call with analysts yesterday, reports the Boston Globe. They said the firm has installed new quality-control systems, but that they are still being tested and that an FDA inspection isn't likely before early next year. It would presumably take a few months after the inspection for the warning letter to be lifted.
October 19, 2006
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
The firm reported third-quarter sales of about $2 billion. That's about 34% higher than for the same period last year, but the growth is due almost entirely to the Guidant acquisition. Sales of its best-selling product, the drug-eluting stent Taxus, actually declined from a year ago, amid concerns from some doctors that the technology can cause clotting.
You May Also Like
.png?width=700&auto=webp&quality=80&disable=upscale)